The biotech IPOs keep coming at chart-topping levels — with no slowdown in sight
Another week, another string of new biotech IPOs — and biotech IPOs pricing at record levels.
In the US, two more early-stage companies broke through the …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
